Allogeneic transplantation of CD34+ -selected cells from peripheral blood in patients with myeloid malignancies in early phase: A case control comparison with unmodified peripheral blood tranplantation

Bone Marrow Transplantation

Volumn 28, Issue 4, 2001, Pages 349-354

  Urbano Ispizua, A ^a   Brunet, S ^b   Solano, C ^c   Moraleda, J M ^d   Rovira, M ^a   Zuazu, J ^e   De La Rubia, J ^f   Bargay, J ^g   Caballero, D ^h   Diez Martin J L ⁱ   Ojeda, E ^j   De Oteiza, J Pérez ^k   Ferra C ^l   Espigado, I ^m   Alegre, A ⁿ   De La Serna, J ^o   Torres, P ^p   Riu, C ^a   Odriozola, J ^k   Rozman, C ^a   Sierra, J ^j   Garcia Conde J ^c   Montserrat, E ^a   more..

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL SANT PAU   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^h HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^j HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^k HOSPITAL RAMÓN Y CAJAL   (Spain)

^l HOSPITAL DURAN I REYNALS   (Spain)

^m HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁿ HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^o HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^p HOSPITAL JUAN CANALEJO   (Spain)

more..

Author keywords

Allogeneic transplantation; CD34+ selection; Peripheral blood progenitor cells

Indexed keywords

CD34 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL SELECTION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY CANCER; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HLA MATCHING; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MYELODYSPLASTIC SYNDROME; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; RECIPIENT; SIBLING; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANTIGENS, CD34; BLOOD TRANSFUSION; CASE-CONTROL STUDIES; CHRONIC DISEASE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 17944383174     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703154     Document Type: Article

References (36)

1. Peripheral blood stem cells for allogeneic transplantation
2. Allogeneic transplantation of blood-derived, T-cell-depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia
3. Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation
4. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: Safety, kinetics of mobilization, and composition of the graft
5. Hematopoietic stem cell transplantation activity in Europe 1999
6. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies
7. Chronic graft-vs-host disease (GVHD) after allogeneic marrow or blood stem cell transplantation
8. High incidence of chronic GVHD after allogeneic peripheral blood progenitor cell transplantation from matched related donors
9. Allogeneic blood stem cell vs bone marrow transplantation; improved leukemia-free survival in high risk but not low risk patients
10. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease
11. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study
12. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation
13. Favorable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced hematologic malignancies
14. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers
15. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: First results of a randomised multicentre trial of the European Group for Marrow Transplantation
16. T-cell depletion of HLA-identical transplants in leukemia
17. + marrow cells for autologous marrow transplantation
18. Positive selection of CD34+ hematopoietic cells using an immunoaffinity column results in T cell-depletion equivalent to elutriation
19. Rapid engraftment without significant GVHD after allogeneic transplantation of CD34+ selected cells from peripheral blood
20. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors
21. Transplantation of positively selected allogeneic blood CD34+ cells
22. Transplantation of allogeneic CD34+ blood cells
23. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy
24. Bone marrow transplantation
25. Regimen-related toxicity in patients undergoing bone marrow transplantation
26. Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: Comparison of recipients of positive CD34+ selected grafts with recipients of unmanipulated grafts
27. T cell depletion of allogeneic peripheral blood stem cells
28. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia: Graft-vs-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
29. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
30. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: Freedom from relapse in the absence of graft-versus-host disease
31. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission
32. Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft
33. Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation
34. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens
35. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial
36. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial